Prime Medicine, Inc.
PRME
Jodie situation report
Prime Medicine, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 21 of 21 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- At least 14 of 21 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as CBLL begins moving with the group.
Invalidation: The live read weakens if participation falls to 7 of 21 members or fewer.
Who this business touches
The relationships behind PRME
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
BEAMBeam Therapeutics Inc.partnerMay 7, 2026 ▾
“Beam Collaboration Agreement — Related Party The Company is currently engaged in arbitration proceedings with Beam Therapeutics, Inc., or Beam, regarding the parties’ collaboration and license agreement, or the Agreement.”
Depended on by
CRSPCRISPR Therapeutics AGcompetitorFeb 12, 2026 ▾
“), Kelonia, Metagenomi, Orbital (recently acquired by Bristol Myers Squibb), Prime Medicine, Sana Biotechnology, Scribe Therapeutics, Tessera Therapeutics, Umoja Biopharma and Verve Therapeutics (recently acquired by Eli Lilly).”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 8 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
PRME is currently a Participant in the organic co-movement group Oncology and Gastrointestinal Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.